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Background and Aims: Obesity is a condition associated with chronic or acute
inflammatory response characterized by an increase of proinflammatory cytokine levels.
Peripheral blood mononuclear cells (PBMCs) migrate in adipose tissue inducing synthesis
and secretion of adipocytokines as IL-6 and TNF-α. The aim of this study was to investigate
the effect of berberine (a natural alkaloid) and red yeast (a natural antioxidant) on IL-6
and TNF-α cytokines release and gene expression, in circulating lipopolisaccarides (LPS)
stimulated PBMCs.
Methods and Results: PBMCs isolated from whole blood of healthy donors were
stimulated with LPS to induce cytokines production; simultaneously cells were treated
with increasing doses of berberine and red yeast. The substances were administered
alone or in association. IL-6 and TNF-α protein levels in the culture medium and their mRNA
levels were assessed by ELISA and real time PCR, respectively. Berberine and red yeast
treatment prevented the LPS induction of IL-6 release in the culture medium of PBMCs.
In addition, berberine plus red yeast treatment showed a synergic inhibitory effect on IL-6
release at low concentration. Berberine and red yeast showed an inhibitory effect also on
LPS induction of TNF-α release exerting a synergic effect mainly at high concentrations.
On the contrary, berberine and red yeast did not significantly affect IL-6 and TNF-α mRNA
levels induced by LPS. In this case, only concomitant treatment of PBMCs with high doses
of berberine and red yeast inhibits LPS induced IL-6 or TNF-α mRNA levels.
Conclusions: The results of our study show that both berberine and red yeast were
able to carry out anti-inflammatory action through an inhibition of proinflammatory IL-6
and TNF-α protein release. Moreover, when given in combination these substances were
able to inhibit IL-6 and TNF-α gene expression in PBMCs activated by LPS. Therefore,
these substances could represent a useful pharmacological treatment to reduce the
proinflammatory status accompanied with obesity.
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INTRODUCTION
Many data indicate that obesity is associated with either a chronic
or an acute inflammatory response characterized by an increase
of cytokine production (Bastard et al., 2006). Recent data show
that circulating mononuclear cells are involved in these increased
proinflammatory proteins production in obese subjects. This
effect seems to bemediated by themigration of mononuclear cells
(MNCs) to arterial wall as well as into adipocyte tissue (Weisberg
et al., 2003), in this tissue, MNCs induce adipocytokines such as
interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) (Solá
et al., 2009).
Some studies indicate that monocytes and macrophages are
strongly increased in the adipose tissue of obese subjects where
they produce proinflammatory cytokines that further increase
the secretion of adipocyte proinflammatory proteins (adipokines)
(Ghanim et al., 2004).
Berberine is an alkaloid extracted from plants belonging to
Berberidaceae family that possesses many biological and phar-
macological effects, such as inhibition of adipogenesis, anti-
inflammatory activity, reduced insulin resistance, and potential
immunomodulatory properties (Choi et al., 2006; Lee et al., 2006;
Yi et al., 2008).
Red Yeast is the product of Monascus purpureus micetes rice
fermentation showing strong antioxidant properties. Monacolin
K, one of the red yeast metabolically active compounds, is
a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor
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effective in reducing the cholesterol synthesis (Lin et al., 2008a).
This is a statin-like effect.
Even if several molecular mechanisms involved in the patho-
genesis of chronic inflammation in obesity take place into adipose
tissue, many studies demonstrate a MNCs involvement in gener-
ating proinflammatory cytokines overexpression in obese subjects
(Ghanim et al., 2004). It is known that MNCs are able either to
migrate through blood vessels in order to generate foam cells,
contributing to atherosclerosis plaques formation, or to migrate
in adipose tissue to produce proinflammatory cytokines like TNF-
α and IL-6 (Weisberg et al., 2003). It is also well known that
lipopolisaccarides (LPS) are recognized by TR4 membrane recep-
tor mainly localized on monocytes/ macrophages membrane
surface; the TR4 receptor activation carries out the production
of many proinflammatory cytokines. Therefore, LPS stimulat-
ing MNCs may provide a representative model of the overall
inflammatory status of body as well as of adipose tissue.
This study was aimed to investigate the effect of berberine and
red yeast on proinflammatory cytokines, IL-6 and TNF-α pro-
tein release, and their expression in LPS stimulated PBMCs from
donors buffy coats. Moreover, this study would further evalu-
ate whether there is a synergism of these molecules in reducing
proinflammatory cytokine levels.
MATERIALS AND METHODS
PBMCs EXTRACTION AND STIMULATION
PBMCs were isolated from healthy donor buffy coats using Ficoll
Paque gradient (GE Healthcare Europe, Munich, Germany). All
samples were obtained in accordance with the requirements of
the hospital ethics committee. The investigation conformed to
the principles outlined in the Declaration of Helsinki (Rickham,
1966).
Briefly, donor blood was diluted 1:10 in PBS 1X and strat-
ified on Ficoll solution with a 3:1 v/v ratio. After a 30min
centrifugation at 2200 r.p.m., PBMCs were recovered and re-
suspended in RPMI-1640 medium supplemented with 10% FCS.
125000/mL PBMCswere cultured at 37◦C in an humidified atmo-
sphere with 5% CO2. MNCs were stimulated with 50 ng/mL LPS
(E. Coli Lipopolisaccarides—Sigma-Aldrich, St. Louis, MO) to
induce cytokines production. Simultaneously, cells were treated
with increasing doses (1, 10 and 50μg/mL) of Berberine and
red yeast containing 1.5% S.C. (Specific Concentration) of the
metabolic active compound Monacolin K, singularly or in asso-
ciation for 3, 6 or 24 h. Red yeast was kindly gifted by Rottapharm
Spa. After incubation cells were recovered with cultured medium
and centrifugated for 5min at 2000 rpm. Supernatants containing
secreted cytokines were collected.
ELISA ASSAY
TNF-α and IL-6 concentrations in diluted (1:100) culture super-
natants were measured by enzyme linked immunosorbent assay
(ELISA) according to instruction of the manufacturer (R&D
Systems ELISA kit Minneapolis MN 55413, USA).
RNA EXTRACTION
After PBMCs stimulation, cells were collected and total RNA
was extracted by using the TRIzol reagent (Invitrogen, Karlsruhe,
Germany). Extracted total RNA was quantified and the ratio
A260/280 was measured to verify its purity.
REAL TIME PCR
0.5μg of total RNA were reverse-transcribed (Invitrogen Life
Technologies Ltd, Paisley, UK) and real time RT-PCR was per-
formed using iCycler Apparatus (Bio-Rad, CA). Forty PCR ampli-
fication cycles of 60 s (15 s, 95◦C; 45 s, 60◦C) were run and ampli-
fication rates were monitored by the Sybr Greenmethod. For PCR
amplification the following primers were used: GAPDHf: GAA
GGT GAA GGT CGG AGT C, GAPDHr: GAA GAT GGT GAT
GGG ATT TC, TNF-αf: AAG AGT TCC CCA GGG ACC TCT,
TNF-αr: CCT GGG AGT AGA TGA GGT ACA, IL-6f: GGA CGG
CTT TTA CTT AAA CGC CAA GG, IL-6r: ATC TTC CCT AGT
TAC CCA GGT TCA GC.
CELL VIABILITY ANALYSIS
The cell viability, performed by Trypan blue test (Doyle and
Griffiths, 1998), was higher than 90% in all the experimental
conditions.
STATISTICAL ANALYSIS
Results were expressed as mean ± SD.
Kruskall-Wallis non parametric analysis of Variance followed
by Mann-Whitney U test were used to compare the results.
RESULTS
BERBERINE AND RED YEAST (1.5% S.C. MONACOLIN K) REDUCE
PROINFLAMMATORY IL-6 AND TNF-α CYTOKINES SECRETION IN LPS
ACTIVATED PBMCs
LPS treatment of PBMCs induced the secretion of proin-
flammatory IL-6 and TNF-α proteins. Berberine treatment
reduced LPS inflammatory response by decreasing IL-6 release
(Figure 1). The anti-inflammatory effect was significant at 3
and 24 h (p < 0.05) (Figures 1A,C). Equally, red yeast reduced
inflammatory response lowering IL-6 release in LPS activated
PBMCs (Figure 1). We observed an inhibition of IL-6 secre-
tion after 3 h and 6 h of treatment with 10 and 50μg/mL red
yeast compared to LPS treated cells (p < 0.05) (Figures 1A,B).
After 24 h of incubation, red yeast significantly decreased IL-
6 release at all the doses used (p < 0.05) (Figure 1C). We
observed that IL-6 secretion inhibition in berberine plus red
yeast stimulated PBMCs cells was more evident at low con-
centration (1μg/mL) and at short time (3 h) (65.2%) (p
< 0.05). In the same conditions, berberine or red yeast
alone inhibited IL-6 secretion by 33% and 3%, respectively
(Figures 1A–C).
Berberine plus red yeast treatment carried out a synergic
inhibitory effect on TNF-α secretion at all the incubation times;
this effect was dose-dependent (Figures 2A–C). After 3 h of treat-
ment the inhibition was equal to 61.5% with the concentration
of 50μg/mL (p < 0.05). After 6 h of incubation the synergic
inhibitory effect was evident at 10 and 50μg/mL (p < 0.05)
(Figure 2B), while TNF-α release was maximally inhibited by
64.7% after 24 h at 50μg/mL of berberine plus red yeast treat-
ment, compared to LPS treatment (p < 0.05) (Figure 2C).
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FIGURE 1 | Anti-inflammatory effects of berberine (B) at 1, 10 and
50μg/mL (B1, B10, B50), red yeast (RY) at 1, 10 e 50μg/mL (RY1, RY10,
RY50) and berberine + red yeast at 1, 10 e 50μg/mL (B+RY1, B+RY10,
B+RY50) at 3 (A), 6 (B) and 24h (C) after LPS stimulation (50ng/mL)
on IL-6 protein levels measured in the incubation medium by ELISA
assay. Asterisks indicate a significant value at Kruskal-Wallis non parametric
analysis of variance followed by Mann-Whitney U test (∗p < 0.05). Values
are means ±SD of three experiments conducted in duplicate.
BERBERINE AND RED YEAST (1.5% S.C. MONACOLIN K) REDUCE IL-6
AND TNF-α mRNA LEVELS IN LPS ACTIVATED PBMCs
Experiments of real time PCRwere carried out starting from RNA
of PBMCs stimulated with LPS. LPS treatment on PBMCs caused
the induction of IL-6 and TNF-α mRNA levels.
Berberine determined a slight reduction of LPS induced IL-6
mRNA levels at 3, 6 and 24 h, that was not statistically signi-
ficative (Figures 3A-C). At the same time, red yeast had not a
significant inhibitory effect on IL-6 mRNA levels (Figures 3A–C).
Differently, concomitant treatment with 50μg/mL, of berberine
and red yeast inhibited LPS induced IL-6 mRNA levels at 3, 6 and
24 h (p < 0.05) of treatment (Figures 3A–C). In addition, TNF-
α inhibition was statistically significant with berberine and red
FIGURE 2 | Anti-inflammatory effects of berberine (B) at 1, 10 and
50μg/mL (B1, B10, B50), red yeast (RY) at 1, 10 e 50μg/mL (RY1, RY10,
RY50) and berberine + red yeast at 1, 10 e 50μg/mL (B+RY1, B+RY10,
B+RY50) at 3 (A), 6 (B), and 24h (C) after LPS stimulation (50ng/mL)
on TNF-α protein protein levels measured in the incubation medium
by ELISA assay. Asterisks indicate a significant value at Kruskal-Wallis non
parametric analysis of variance followed by Mann-Whitney U test
(∗p < 0.05). Values are means ±SD of three experiments conducted in
duplicate.
yeast concomitant treatment at 3 h (p < 0.05), but not at 6 and
24 h (Figures 4A–C).
DISCUSSION
It has been previously demonstrated that mononuclear cells
MNCs in obese subjects are involved in proinflammatory state
with increased formation of proinflammatory transcriptional
intranuclear factor kB (NF-kB) and proinflammatory genes
regulated by NF-kB (Ghanim et al., 2004). Berberine anti-
inflammatory effects have been largely demonstrated both in
animal models and in other experimental systems (Ivanovska and
Philipov, 1996). In addition, experimental evidence indicate a
decrease of mRNA levels of inflammation marker (TNF-α, IL-6
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FIGURE 3 | Anti-inflammatory effects of berberine (B) at 1, 10 and 50
μg/mL (B1, B10, B50), red yeast (RY) at 1, 10 e 50 μg/mL (RY1, RY10,
RY50) and berberine + red yeast at 1, 10 e 50 μg/mL (B+RY1, B+RY10,
B+RY50) at 3 (A), 6 (B), and 24h (C) after LPS stimulation (50ng/mL)
on IL-6 mRNA levels measured by RT-PCR. Asterisks indicate a significant
value at Kruskal-Wallis non parametric analysis of variance followed by
Mann-Whitney U test (∗p < 0.05). Values are means ±SD of three
experiments conducted in duplicate.
and CRP) in berberine-treated immortalized 3T3-L1 adipocytes
(Choi et al., 2006). In the last years, moreover, different stud-
ies have demonstrated red yeast anti-inflammatory effects (Chen
et al., 2008; Lin et al., 2008b).
The results of our study show that both berberine and red
yeast carried out anti-inflammatory action through an inhibi-
tion of proinflammatory cytokines, IL-6 and TNF-α release and
their gene expression in PBMCs activated by LPS. It is worth not-
ing that berberine and red yeast were active in a synergistic way;
we observed that IL-6 secretion inhibition in berberine plus red
yeast stimulated PBMCs cells was more evident at low concen-
tration (1μg/mL) and at short time (3 h) (65.2%). In the same
conditions, berberine or red yeast alone inhibited IL-6 secretion
by 33% and 3%, respectively. Synergistic effect of berberine and
red yeast was also evident in TNF-α secretion inhibition; in this
case this synergism appreciated during entire time-course (3, 6 e
24 h), but at high concentration (50μg/mL). Berberine plus red
yeast were effective in a synergistic way also during cytokines tran-
scription or post-transcription events regulating mRNA levels. It
FIGURE 4 | Anti-inflammatory effects of berberine (B) at 1, 10 and 50
μg mg/mL (B1, B10, B50), red yeast (RY) at 1, 10 e 50 mg/mL (RY1,
RY10, RY50) and berberine + red yeast at 1, 10 e 50 μg/mL (B+RY1,
B+RY10, B+RY50) at 3 (A), 6 (B), and 24h (C) after LPS stimulation
(50ng/mL) on TNF-α mRNA levels measured by RT-PCR. Asterisks
indicate a significant value (p < 0.05 at Kruskal-Wallis non parametric
analysis of variance followed by Mann-Whitney U test). Values are means
±SD of three experiments conducted in duplicate.
is evident from our data that, except for the combination of both
compounds, there is no effect of both substances administered
alone onmRNA levels of TNF-α or IL-6. Nevertheless, this suggest
that both substances carried out an effect at post-transcriptional
level even if this hypothesis needs further investigation.
Recent studies have shown berberine protective effect in the
treatment of metabolic disorders such as body weight reduc-
tion, cholesterol, and glycemia level reduction (Lee et al., 2006;
Yin et al., 2008; Affuso et al., 2010). In addition, several studies
attribute to berberine an anti-obesity effect, because it is able to
inhibit adipogenesis (Choi et al., 2006; Huang et al., 2006; Kim
et al., 2007; Yi et al., 2008; Hu and Davies, 2010). It has been
reported that monacolin K is a red yeast metabolically active com-
pound effective in plasma lipid lowering (Cicero et al., 2010).
According to previous data (Bastard et al., 2000; Juge-Aubry et al.,
2004; Aygun et al., 2005; Park et al., 2005), our results indi-
cate that the induction of proinflammatory cytokines, IL-6 and
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TNF-α production, caused in PBMs stimulated by LPS, is simi-
lar to that observed in obese subject, where metabolic disorders,
proinflammatory state and insulin resistance are often associ-
ated. Therefore, our study suggests that berberine and red yeast
could represent a useful pharmacological approach to reduce
proinflammatory status associated with these pathologies.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://www.frontiersin.org/journal/10.3389/fphar.
2014.00230/abstract
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